KYMR

SEC source: 0001209191-21-049922 · doc4.xml · derivative · entry 6

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,725

Underlying: Common Stock · 1,037 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 453,236

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-049922 · doc4.xml · derivative · entry 5

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,762

Underlying: Common Stock · 5,669 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-049922 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 457,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-049110 · doc4.xml · derivative · entry 11

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,431

Underlying: Common Stock · 23,456 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 8

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.205 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 7

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,499

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.00 to $61.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 6

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 454,023

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 5

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-049110 · doc4.xml · derivative · entry 10

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,887

Underlying: Common Stock · 6,279 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-049110 · doc4.xml · derivative · entry 9

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,166

Underlying: Common Stock · 680 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

SEC source: 0001209191-21-049110 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,879

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-048437 · doc4.xml · derivative · entry 6

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,846

Underlying: Common Stock · 3,864 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-048437 · doc4.xml · derivative · entry 5

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,710

Underlying: Common Stock · 9,015 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-048437 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 461,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-046174 · doc4.xml · derivative · entry 6

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,725

Underlying: Common Stock · 48,000 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 5

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.60 to $51.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,794

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.45 to $51.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 459,166

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.44 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 482,969

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.44 to $49.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001209191-21-046174 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000921895-21-001789 · form407422kymr_07062021.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,538

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F8 · balance_after: The total number reported contains a de minimis correction to the balance on the Reporting Person's previous Form 4 filed on June 21, 2021.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-21-001789 · form407422kymr_07062021.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,229,017

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F8 · balance_after: The total number reported contains a de minimis correction to the balance on the Reporting Person's previous Form 4 filed on June 21, 2021.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-21-001789 · form407422kymr_07062021.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,664,104

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F8 · balance_after: The total number reported contains a de minimis correction to the balance on the Reporting Person's previous Form 4 filed on June 21, 2021.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000899243-21-025048 · doc4.xml · derivative · entry 1

Caughey Elaine · CIK 0001868668 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-06-20

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option shall vest on June 21, 2022, and the remainder shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-21-024448 · doc4.xml · derivative · entry 1

Nicholson Donald William · CIK 0001814617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-024447 · doc4.xml · derivative · entry 1

Esposito Pamela · CIK 0001744425 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-024443 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-024445 · doc4.xml · derivative · entry 1

Horobin Joanna · CIK 0001560959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-024442 · doc4.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-21-024439 · doc4.xml · derivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-21-024432 · doc4.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-024431 · doc4.xml · derivative · entry 1

Hall Steven Edward · CIK 0001602732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,063

Underlying: Common Stock · 20,063 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000921895-21-001667 · form407422010_06172021.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 20,063

Underlying: Common Stock, $0.0001 par value · 20,063 shares

Expires 2031-06-15

F6 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F7 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F6 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0000899243-22-014880 · doc4a.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,459

Underlying: Common Stock · 10,459 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-023664 · doc4.xml · derivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,424

Underlying: Common Stock · 40,000 shares

Expires 2029-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-21-023664 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-023228 · doc4.xml · derivative · entry 5

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,725

Underlying: Common Stock · 23,009 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.

SEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,199

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.02 to $52.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,193

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,105

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.